Sankalp Gokhale
Chief Tech/Sci/R&D Officer chez DIANTHUS THERAPEUTICS, INC.
Profil
Sankalp Gokhale is currently working as the Vice President-Clinical Development at Dianthus Therapeutics, Inc. Prior to this, he held positions as the Medical Director-Clinical Development at Alexion Pharmaceuticals, Inc. and as the Senior Director-Clinical Development at Radius Health, Inc. Dr. Gokhale obtained an MBA from the University of Arizona.
Postes actifs de Sankalp Gokhale
| Sociétés | Poste | Début |
|---|---|---|
| DIANTHUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 11/09/2023 |
Anciens postes connus de Sankalp Gokhale
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| RADIUS HEALTH, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Sankalp Gokhale
| University of Arizona | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DIANTHUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
